Navigating the Complexities of Hypertrophic Cardiomyopathy: Payer Considerations on Strategies for Comprehensive Management

Learn About:

Guideline recommendations for the diagnosis and management of hypertrophic cardiomyopathy (HCM)
Considerations for pharmacologic management of patients with HCM
Shared decision-making in the management of HCM and opportunities for managed care professionals to support patient-centered care

Expert Faculty Presenters


	Steven S. Kheloussi, PharmD, MBA, FAMCP (Moderator) Principal Consultant Kheloussi Consulting, LLC Click here for biography

	Nosheen Reza, MD, MS, FACC, FHFSA Assistant Professor of Medicine Penn Center for Inherited Cardiovascular Disease Section of Advanced Heart Failure, Transplantation, and Mechanical Support Director, Penn Women in Cardiology Program Division of Cardiovascular Medicine Hospital of the University of Pennsylvania & the Perelman School of Medicine at the University of Pennsylvania Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Through a multidisciplinary discussion format, the webcast will address critical gaps in payer understanding of hypertrophic cardiomyopathy (HCM), including guideline interpretation, coverage implications, emerging pharmacologic options such as cardiac myosin inhibitors, and the importance of shared decision‑making to support individualized, high‑quality care. Using real‑world HCM case scenarios, the faculty will explore strategies to optimize benefit design, prior authorization, and access pathways to improve clinical and economic outcomes across health systems. Learners will receive targeted, practical insights that can help payers implement evidence‑based policies that enhance appropriate, timely treatment for patients with HCM.

Educational Objectives
After completing this activity, the participant should be better able to:

Interpret guideline recommendations for the diagnosis and management of HCM, including implications for payer coverage policies and clinical decision support
Describe the mechanism of action, clinical role, and coverage considerations for pharmacologic management of patients with HCM inadequately managed with first-line therapy
Assess the role of shared decision-making in the management of HCM and identify opportunities for managed care professionals to support patient-centered care through policies that facilitate access to individualized testing and treatment options

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources, Inc., and Impact Education, LLC. Medical Education Resources is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 0.75 contact hour (0.075 CEU) of the Accreditation Council for Pharmacy Education.

UAN: Coming Soon
Type of Activity: Knowledge-based

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
Medical Education Resources designates this enduring activity for a maximum of 0.75 ANCC nursing contact hour.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 0.75 contact hour.

Disclosure of All Financial Relationships
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

*Name of Faculty*	*Reported Financial Relationship*
Steven S. Kheloussi, PharmD, MBA, FAMCP	No financial relationships to disclose
Nosheen Reza, MD, MS, FACC, FHFSA	Grants/Research Support: Bristol Myers Squibb Consulting Fees: Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, American Regent, AstraZeneca, Idorsia, Novo Nordisk

The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

*Name of Content Manager*	*Reported Financial Relationship*
Planners at Impact Education, LLC	No financial relationships to disclose
Planners at Medical Education Resources	No financial relationships to disclose

METHOD OF PARTICIPATION
There are no fees for participating in and receiving credit for this activity. During the accreditation period, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, and 3) complete the evaluation form.

MEDIA
Internet

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Cytokinetics. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

FEE INFORMATION
There is no fee for this educational activity.